Renal Cell Carcinoma Perspective

 
 
  • Find Individuals That Inspire You   Eric Jonasch, MD, reflects on the impact that his mentor had on his philosophy and approach to the treatment of patients with renal cell carcinoma.
  • Unmet Needs in the Era of Precision Medicine for RCC   Sandy Srinivas, MD, examines the current unmet needs for patients with renal cell carcinoma and discusses how the KEYNOTE-564 trial can help identify the right patient for the right therapy.
  • RCC e-Tumor Boards: Case 1: Metastatic Clear Cell Renal Cell Carcinoma   The e-Tumor Boards, a video series collaboration with Memorial Sloan Kettering Cancer Center, gives physicians an inside look into a virtual, multidisciplinary renal cell carcinoma tumor board case discussion.
  • Renal Cell Carcinoma Highlights From ESMO 2021   Dr Brian Rini, of Vanderbilt University, discusses key RCC abstracts from ESMO 2021, including data on efficacy and quality-of-life endpoints from the STAR, PRISM, and KEYNOTE-564 trials.
  • AUA 2021 Read clinically focused news coverage of key developments from AUA 2021
  • EAU 2021 Read clinically focused news coverage of key developments from EAU 2021
  • Highlights in Renal Cell Carcinoma From ASCO 2021   From ASCO 2021, Dr Eric Jonasch reports on advances for patients with renal cell carcinoma, including results from the KEYNOTE-564 study and the quality-of-life update from the CLEAR trial.
  • Highlights in RCC From ASCO 2021 GU Cancers Symposium   From ASCO GU 2021, Dr Daniel George reports on advances for patients with renal cell carcinoma, including results from the CLEAR study, CheckMate 9ER, and SWOG 1500.
  • GUCS 2021 Read clinically focused news coverage of key developments from GUCS 2021
  • Metastatic RCC Highlights From IKCS 2020   Dr Brian Rini reports key results in metastatic RCC from IKCS 2020, including early evidence of benefit from lenvatinib-everolimus in non-clear cell RCC, and an alternative ipilimumab-nivolumab dose.
  • Renal Cell Carcinoma Highlights From ESMO 2020   Dr Robert Motzer reviews key studies on renal cell carcinoma presented at the 2020 ESMO Virtual Congress, including phase 3 trial results showing benefit from combination therapies in advanced RCC.
  • ASCO Plenary Highlights Importance of Publicly Funded Research The question posited by the E2108 study, which is being presented at this year's ASCO annual meeting, may not have a financial incentive, but it is vital for clinical practice.
  • AUA 2020 Read clinically focused news coverage of key developments from AUA 2020
  • Will Coronavirus Restrictions Lead to More Advanced Cancers? The coronavirus epidemic will almost certainly shed new light on restricted medical procedures like cancer screening going forward.
  • GUCS 2020 Read clinically focused news coverage of key developments from GUCS 2020
  • Top 5 Advances in Lung Cancer Immunotherapy Over the Past Decade Lung cancer experts Jack West and Charu Aggarwal highlight the biggest immunotherapy trials in thoracic oncology from 2010 to 2019.
  • Fecal Transplants: 5 Things to Know Research continues to expand regarding potential uses of fecal microbiota transplantation, but safety concerns are growing following a patient's death. Here are the latest data you need to know.
  • Renal Cell Carcinoma: 5 Things to Know What you need to know about the latest data on treating this common cancer.
  • Setbacks and Advances in Renal Cell Carcinoma Treatment Although we have more evidence against tyrosine kinase inhibitors in the adjuvant setting, studies on immunotherapy and surveillance point toward progress.
  • Checkpoint Inhibitors: Powerful Drugs With Severe Side Effects Would you recognize a cutaneous adverse effect of these powerful agents? A new study can help -- and provides key information about management.